ResearcherKyushu UniversityNo recent work listed
Ken Kawabe
Matched on ORCID iD 0000-0001-7235-8560; OpenAlex author ID A5014811179. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 42
2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper
Papers 4
- Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyac157↗
- nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. Co-author DOI 10.1002/cam4.3558↗
- [Massive biliary hemorrhage due to rupture of pseudoaneurysm after endoscopic biliary plastic stenting for pancreatic cancer]. Last author DOI 10.11405/nisshoshi.116.754↗
- Familial pancreatic cancer: Concept, management and issues. Co-author DOI 10.3748/wjg.v23.i6.935↗
Closest collaborators
The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Junji Furuse · 3 shared papers, 2017–2022 · strength 0.24
- Paper Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unre… DOI 10.1093/oncolo/oyac157↗
- Paper nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese p… DOI 10.1002/cam4.3558↗
- Paper Familial pancreatic cancer: Concept, management and issues. DOI 10.3748/wjg.v23.i6.935↗
- Makoto Ueno · 3 shared papers, 2017–2022 · strength 0.24
- Paper Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unre… DOI 10.1093/oncolo/oyac157↗
- Paper nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese p… DOI 10.1002/cam4.3558↗
- Paper Familial pancreatic cancer: Concept, management and issues. DOI 10.3748/wjg.v23.i6.935↗
- Hiroshi Ishii · 2 shared papers, 2020–2022 · strength 0.19
- Paper Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unre… DOI 10.1093/oncolo/oyac157↗
- Paper nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese p… DOI 10.1002/cam4.3558↗
- Masato Ozaka · 2 shared papers, 2020–2022 · strength 0.19
- Paper Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unre… DOI 10.1093/oncolo/oyac157↗
- Paper nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese p… DOI 10.1002/cam4.3558↗
- Masayuki Furukawa · 2 shared papers, 2017–2020 · strength 0.14
- Yohei Kitano · 1 shared paper, 2022 · strength 0.10
- Hiroaki Nagano · 1 shared paper, 2022 · strength 0.10
- Shiho Arima · 1 shared paper, 2022 · strength 0.10
- Kunihiro Tsuji · 1 shared paper, 2022 · strength 0.10
- Kumiko Umemoto · 1 shared paper, 2022 · strength 0.10
- Satoshi Kobayashi · 1 shared paper, 2022 · strength 0.10
- Rei Suzuki · 1 shared paper, 2022 · strength 0.10
- Naohiro Okano · 1 shared paper, 2022 · strength 0.10
- Hideyuki Hayashi · 1 shared paper, 2022 · strength 0.10
- Akiko Todaka · 1 shared paper, 2022 · strength 0.10
- Hironori Yamaguchi · 1 shared paper, 2022 · strength 0.10
- Hiroshi Imaoka · 1 shared paper, 2022 · strength 0.10
- Masatoshi Murakami · 1 shared paper, 2019 · strength 0.10
- Shoji Nakamori · 1 shared paper, 2020 · strength 0.09
- Atsushi Satō · 1 shared paper, 2020 · strength 0.09
- Tatsuya Ioka · 1 shared paper, 2020 · strength 0.09
- Yoshito Komatsu · 1 shared paper, 2020 · strength 0.09
- Masafumi Ikeda · 1 shared paper, 2020 · strength 0.09
- Masashi Kanai · 1 shared paper, 2020 · strength 0.09
- Takuji Okusaka · 1 shared paper, 2020 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.